Sonora Investment Management, LLC - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 22 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Sonora Investment Management, LLC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q1 2021$3,000
+50.0%
4660.0%0.00%
Q4 2020$2,0000.0%466
-93.3%
0.00%
Q3 2020$2,000
-60.0%
7,0000.0%0.00%
-100.0%
Q2 2020$5,000
+150.0%
7,0000.0%0.00%
Q1 2020$2,000
-60.0%
7,0000.0%0.00%
Q4 2019$5,0000.0%7,0000.0%0.00%
-100.0%
Q3 2019$5,000
-58.3%
7,0000.0%0.00%0.0%
Q2 2019$12,000
-33.3%
7,0000.0%0.00%
-50.0%
Q1 2019$18,0000.0%7,0000.0%0.00%
-33.3%
Q4 2018$18,000
-40.0%
7,000
+16.7%
0.00%
-25.0%
Q3 2018$30,000
+172.7%
6,000
+71.4%
0.00%
+100.0%
Q2 2018$11,000
-99.9%
3,5000.0%0.00%0.0%
Q1 2018$12,670,000
+78.3%
3,5000.0%0.00%
+100.0%
Q4 2017$7,105,000
-24.0%
3,500
-36.4%
0.00%
-50.0%
Q3 2017$9,350,000
+0.4%
5,500
+57.1%
0.00%0.0%
Q2 2017$9,310,000
-61.6%
3,5000.0%0.00%
-60.0%
Q1 2017$24,220,000
+208.9%
3,5000.0%0.01%
+150.0%
Q4 2016$7,840,000
-1.3%
3,5000.0%0.00%0.0%
Q3 2016$7,945,000
-16.5%
3,5000.0%0.00%0.0%
Q2 2016$9,520,000
-6.5%
3,5000.0%0.00%0.0%
Q1 2016$10,185,000
+145400.0%
3,500
+133.3%
0.00%0.0%
Q4 2015$7,000
+133.3%
1,500
+200.0%
0.00%
+100.0%
Q3 2015$3,0005000.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q3 2015
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 2,675,889$6,797,0005.97%
PERKINS CAPITAL MANAGEMENT INC 449,950$1,143,0000.89%
Diametric Capital, LP 116,754$297,0000.23%
Granahan Investment Management 924,300$2,348,0000.17%
Requisite Energy Fund I LP 100,000$254,0000.10%
Requisite Capital Management, LLC 100,000$254,0000.10%
B. Riley Wealth Advisors, Inc. 250,000$635,0000.09%
Kalos Management, Inc. 74,420$179,0000.09%
Crow Point Partners, LLC 65,475$164,0000.03%
ARDSLEY ADVISORY PARTNERS LP 35,000$89,0000.02%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders